APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Therapeutics

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Selected research

Market Outlook & Growth Opportunities

Global Oligonucleotide Therapeutics Market Outlook and Growth Opportunities 2026

31 December 2025195 pages

Choose your research edition.

Industry ResearchOligonucleotide Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Therapeutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

Read the full market overview

This report provides an overview of the global Oligonucleotide Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oligonucleotide Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oligonucleotide Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oligonucleotide Therapeutics market.

Oligonucleotide Therapeutics Segment by Company

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Bausch & Lomb

Alnylam Pharmaceuticals

Dynavax Technologies

Kastle therapeutics

Akcea Therapeutics

Oligonucleotide Therapeutics Segment by Type

Antisense Oligonucleotide

Aptamer

Other

Oligonucleotide Therapeutics Segment by Application

Neuromuscular Diseases

ATTR

Hepatic VOD

Other

Oligonucleotide Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oligonucleotide Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oligonucleotide Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Oligonucleotide Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oligonucleotide Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oligonucleotide Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Oligonucleotide Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotide Therapeutics industry.

Chapter 3: Detailed analysis of Oligonucleotide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oligonucleotide Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oligonucleotide Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oligonucleotide Therapeutics Industry Trends Table 2. Oligonucleotide Therapeutics Industry Drivers Table 3. Oligonucleotide Therapeutics Industry Opportunities and Challenges Table 4. Oligonucleotide Therapeutics Industry Restraints Table 5. Global Oligonucleotide Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oligonucleotide Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Oligonucleotide Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oligonucleotide Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Oligonucleotide Therapeutics Company, Product Type & Application Table 10. Global Oligonucleotide Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oligonucleotide Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antisense Oligonucleotide Table 15. Significant Companies of Aptamer Table 16. Significant Companies of Other Table 17. Global Oligonucleotide Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Oligonucleotide Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Oligonucleotide Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Oligonucleotide Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Oligonucleotide Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Neuromuscular Diseases Table 23. Significant Companies of ATTR Table 24. Significant Companies of Hepatic VOD Table 25. Significant Companies of Other Table 26. Global Oligonucleotide Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oligonucleotide Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Oligonucleotide Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Oligonucleotide Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global Oligonucleotide Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global Oligonucleotide Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oligonucleotide Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Oligonucleotide Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global Oligonucleotide Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Oligonucleotide Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global Oligonucleotide Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Oligonucleotide Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Oligonucleotide Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global Oligonucleotide Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Oligonucleotide Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. Biogen Company Information Table 42. Biogen Business Overview Table 43. Biogen Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Biogen Oligonucleotide Therapeutics Product Portfolio Table 45. Biogen Recent Development Table 46. Sarepta Therapeutics Company Information Table 47. Sarepta Therapeutics Business Overview Table 48. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio Table 50. Sarepta Therapeutics Recent Development Table 51. Jazz Pharmaceuticals Company Information Table 52. Jazz Pharmaceuticals Business Overview Table 53. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio Table 55. Jazz Pharmaceuticals Recent Development Table 56. Bausch & Lomb Company Information Table 57. Bausch & Lomb Business Overview Table 58. Bausch & Lomb Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio Table 60. Bausch & Lomb Recent Development Table 61. Alnylam Pharmaceuticals Company Information Table 62. Alnylam Pharmaceuticals Business Overview Table 63. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio Table 65. Alnylam Pharmaceuticals Recent Development Table 66. Dynavax Technologies Company Information Table 67. Dynavax Technologies Business Overview Table 68. Dynavax Technologies Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio Table 70. Dynavax Technologies Recent Development Table 71. Kastle therapeutics Company Information Table 72. Kastle therapeutics Business Overview Table 73. Kastle therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio Table 75. Kastle therapeutics Recent Development Table 76. Akcea Therapeutics Company Information Table 77. Akcea Therapeutics Business Overview Table 78. Akcea Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio Table 80. Akcea Therapeutics Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Oligonucleotide Therapeutics Product Image Figure 2. Global Oligonucleotide Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Oligonucleotide Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antisense Oligonucleotide Image Figure 8. Aptamer Image Figure 9. Other Image Figure 10. Global Oligonucleotide Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Oligonucleotide Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Oligonucleotide Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Neuromuscular Diseases Image Figure 14. ATTR Image Figure 15. Hepatic VOD Image Figure 16. Other Image Figure 17. Global Oligonucleotide Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Oligonucleotide Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Oligonucleotide Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global Oligonucleotide Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Oligonucleotide Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Oligonucleotide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Oligonucleotide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Oligonucleotide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Oligonucleotide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Oligonucleotide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Oligonucleotide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Oligonucleotide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Oligonucleotide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Oligonucleotide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Oligonucleotide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotide
  • Aptamer
  • Other
Applications
  • Neuromuscular Diseases
  • ATTR
  • Hepatic VOD
  • Other
Companies covered
  • Biogen
  • Sarepta Therapeutics
  • Jazz Pharmaceuticals
  • Bausch & Lomb
  • Alnylam Pharmaceuticals
  • Dynavax Technologies
  • Kastle therapeutics
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oligonucleotide Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oligonucleotide Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oligonucleotide Therapeutics Market Dynamics
  1. 2.1 Oligonucleotide Therapeutics Industry Trends
  2. 2.2 Oligonucleotide Therapeutics Industry Drivers
  3. 2.3 Oligonucleotide Therapeutics Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide Therapeutics Industry Restraints
3 Oligonucleotide Therapeutics Market by Company
  1. 3.1 Global Oligonucleotide Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Oligonucleotide Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Oligonucleotide Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Oligonucleotide Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Oligonucleotide Therapeutics Company Product Type and Application
  6. 3.6 Global Oligonucleotide Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oligonucleotide Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oligonucleotide Therapeutics Market by Type
  1. 4.1 Oligonucleotide Therapeutics Type Introduction
  2. 4.1.1 Antisense Oligonucleotide
  3. 4.1.2 Aptamer
  4. 4.1.3 Other
  5. 4.2 Global Oligonucleotide Therapeutics Sales Value by Type
  6. 4.2.1 Global Oligonucleotide Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oligonucleotide Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Oligonucleotide Therapeutics Sales Value Share by Type (2021-2032)
5 Oligonucleotide Therapeutics Market by Application
  1. 5.1 Oligonucleotide Therapeutics Application Introduction
  2. 5.1.1 Neuromuscular Diseases
  3. 5.1.2 ATTR
  4. 5.1.3 Hepatic VOD
  5. 5.1.4 Other
  6. 5.2 Global Oligonucleotide Therapeutics Sales Value by Application
  7. 5.2.1 Global Oligonucleotide Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oligonucleotide Therapeutics Sales Value by Application (2021-2032)
  9. 5.2.3 Global Oligonucleotide Therapeutics Sales Value Share by Application (2021-2032)
6 Oligonucleotide Therapeutics Regional Value Analysis
  1. 6.1 Global Oligonucleotide Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oligonucleotide Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oligonucleotide Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oligonucleotide Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oligonucleotide Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Oligonucleotide Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oligonucleotide Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Oligonucleotide Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oligonucleotide Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oligonucleotide Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oligonucleotide Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Oligonucleotide Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oligonucleotide Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oligonucleotide Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Oligonucleotide Therapeutics Country-level Value Analysis
  1. 7.1 Global Oligonucleotide Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oligonucleotide Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oligonucleotide Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oligonucleotide Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oligonucleotide Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oligonucleotide Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oligonucleotide Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Oligonucleotide Therapeutics Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Sarepta Therapeutics
  8. 8.2.1 Sarepta Therapeutics Company Information
  9. 8.2.2 Sarepta Therapeutics Business Overview
  10. 8.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio
  12. 8.2.5 Sarepta Therapeutics Recent Developments
  13. 8.3 Jazz Pharmaceuticals
  14. 8.3.1 Jazz Pharmaceuticals Company Information
  15. 8.3.2 Jazz Pharmaceuticals Business Overview
  16. 8.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
  18. 8.3.5 Jazz Pharmaceuticals Recent Developments
  19. 8.4 Bausch & Lomb
  20. 8.4.1 Bausch & Lomb Company Information
  21. 8.4.2 Bausch & Lomb Business Overview
  22. 8.4.3 Bausch & Lomb Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio
  24. 8.4.5 Bausch & Lomb Recent Developments
  25. 8.5 Alnylam Pharmaceuticals
  26. 8.5.1 Alnylam Pharmaceuticals Company Information
  27. 8.5.2 Alnylam Pharmaceuticals Business Overview
  28. 8.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
  30. 8.5.5 Alnylam Pharmaceuticals Recent Developments
  31. 8.6 Dynavax Technologies
  32. 8.6.1 Dynavax Technologies Company Information
  33. 8.6.2 Dynavax Technologies Business Overview
  34. 8.6.3 Dynavax Technologies Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio
  36. 8.6.5 Dynavax Technologies Recent Developments
  37. 8.7 Kastle therapeutics
  38. 8.7.1 Kastle therapeutics Company Information
  39. 8.7.2 Kastle therapeutics Business Overview
  40. 8.7.3 Kastle therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio
  42. 8.7.5 Kastle therapeutics Recent Developments
  43. 8.8 Akcea Therapeutics
  44. 8.8.1 Akcea Therapeutics Company Information
  45. 8.8.2 Akcea Therapeutics Business Overview
  46. 8.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio
  48. 8.8.5 Akcea Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst